Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Kidney and glitazones].

G Deray1, H Izzedine, V Launay-Vacher

  • 1Service de Néphrologie, Groupe Hospitalier Pitié-Salpêtrière, F-75651 Paris Cedex 13, France. gilbert.deray@psl.ap-hop-paris.fr

Annales D'Endocrinologie
|June 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiotics and chronic kidney disease: Dose adjustment update for infectious disease clinical practice.

Medecine et maladies infectieuses·2019
Same author

Anticoagulants in frail patients. Seven situations at risk.

Journal de medecine vasculaire·2018
Same author

Renal function and venous thromboembolic diseases.

Journal des maladies vasculaires·2016
Same author

Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

The eye: a window on kidney diseases.

Clinical kidney journal·2015
Same author

Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same journal

Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.

Annales d'endocrinologie·2026
Same journal

Clinical and genetic diagnosis of PHP1A associated with hypogonadism in a young male: A case report.

Annales d'endocrinologie·2026
Same journal

Autoimmune features in acquired generalized lipodystrophy and anti-perilipin 1 antibodies: A case report.

Annales d'endocrinologie·2026
Same journal

The diagnostic challenge of occult glucocorticoid exposure causing Cushing's syndrome.

Annales d'endocrinologie·2026
Same journal

ACTH-dependent Cushing's syndrome in MEN1: When multiple tumors complicate the diagnosis.

Annales d'endocrinologie·2026
See all related articles

Glitazones, PPARgamma agonists, show promise in managing blood pressure and diabetic nephropathy in type 2 diabetes. Further research is needed to fully characterize their benefits and potential side effects.

Area of Science:

  • Endocrinology
  • Nephrology
  • Pharmacology

Context:

  • Peroxisome proliferator-activated receptor gamma (PPARgamma) nuclear receptors are expressed in adipose, renal glomerular, and vascular tissues.
  • PPARgamma plays a role in glomerular and vascular sclerosis, and the development/progression of nephropathy.

Purpose:

  • To investigate the effects of glitazones, PPARgamma agonists, on blood pressure and diabetic nephropathy.
  • To evaluate the potential of glitazones in managing hypertension and renal complications in type 2 diabetes.

Summary:

  • Experimental studies (in vitro and animal models) demonstrate glitazones favorably impact blood pressure and prevent/slow diabetic nephropathy progression.
  • Limited clinical studies in type 2 diabetic patients suggest beneficial effects on blood pressure and nephropathy.

Related Experiment Videos

Impact:

  • Glitazones may offer a therapeutic strategy for managing hypertension and diabetic nephropathy in type 2 diabetes.
  • Further clinical studies are warranted to establish and characterize glitazone effects across various conditions.
  • Glitazones are easily administered in patients with renal insufficiency without dosage adjustments.